NO961571L - Nytt, mitotisk kjernefosfoprotein: mitosin - Google Patents
Nytt, mitotisk kjernefosfoprotein: mitosinInfo
- Publication number
- NO961571L NO961571L NO961571A NO961571A NO961571L NO 961571 L NO961571 L NO 961571L NO 961571 A NO961571 A NO 961571A NO 961571 A NO961571 A NO 961571A NO 961571 L NO961571 L NO 961571L
- Authority
- NO
- Norway
- Prior art keywords
- mitosine
- protein
- nucleic acid
- phase
- acid molecule
- Prior art date
Links
- 102000007982 Phosphoproteins Human genes 0.000 title abstract 2
- 108010089430 Phosphoproteins Proteins 0.000 title abstract 2
- 230000000394 mitotic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000011278 mitosis Effects 0.000 abstract 1
- 230000027291 mitotic cell cycle Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Nytt, renset fosfoprotein. betegnet mitosin, er tilveiebrakt ved. hjelp av denne oppfinnelsen. Også tilveiebrakt er aminosyresekvensen og nukleinsyremolekylet som tilsvarer mito-sinprotein. Diagnostiske og terapeut-iske fremgangsmåter hvor protein- og. nukleinsyremolekylet anvendes, er også. tilveiebrakt. Et nukleinsyremolekyl som. koder for mitosin, er også tilveiebrakt. ved hjelp av denne oppfinnelsen, samt. aktive fragmenter derav. Nukleinsyre-I molekylene kan anvendes til å frem-stille mitosin rekombinant, og for an-vendelse som prober. Preparatene og. fremgangsmåtene ifølge denne oppfinnelsen er basert på den umiddelbare opp-dagelse at den intracellulære tilstede-værelse av mitosin er nødvendig for at. en eukaryot celle skal komme inn i M-fasen av mitose, og at nedbrytningen av. mitosin er nødvendig for at cellen skal. avansere videre til det neste stadium.Et anti-mitosin-antistoff, en mutant. eller en ikke-funksjonell analog av. mitosin ville således inhibere den. mitotiske cellesyklus ved å forhindre. celler fra å komme inn i M-fasen, og. overekspresjon av mitosin, eller av en. funksjonell ekvivalent derav, ville. inhibere syklusen ved å forhindre celler fra å forlate M-fasen. Slik. overekspresjon ville kunne oppnås enten ved tilsetning av proteinet eller gjen-nom genterapi, dvs. tilførsel av et gen som koder for proteinet eller en funksjonell ekvivalent derav.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14123993A | 1993-10-22 | 1993-10-22 | |
| PCT/US1994/012162 WO1995011309A2 (en) | 1993-10-22 | 1994-10-24 | A novel nuclear mitotic phosphoprotein: mitosin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO961571D0 NO961571D0 (no) | 1996-04-19 |
| NO961571L true NO961571L (no) | 1996-06-24 |
Family
ID=22494806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO961571A NO961571L (no) | 1993-10-22 | 1996-04-19 | Nytt, mitotisk kjernefosfoprotein: mitosin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5710022A (no) |
| EP (1) | EP0723595A1 (no) |
| JP (1) | JPH09507744A (no) |
| CN (1) | CN1133616A (no) |
| AU (1) | AU8088594A (no) |
| BR (1) | BR9407874A (no) |
| CA (1) | CA2173978A1 (no) |
| CZ (1) | CZ111996A3 (no) |
| FI (1) | FI961665A7 (no) |
| HU (1) | HUT74839A (no) |
| NO (1) | NO961571L (no) |
| PL (1) | PL314179A1 (no) |
| SK (1) | SK48996A3 (no) |
| WO (1) | WO1995011309A2 (no) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384735B1 (en) | 1986-08-11 | 2008-06-10 | Massachusetts Eye And Ear Infirmary | Retinoblastoma nucleic acids |
| US7223842B1 (en) | 1986-08-11 | 2007-05-29 | Massachusetts Eye And Ear Infirmary | Detection of proteins whose absence is associated with a neoplasm |
| US20030086927A1 (en) * | 1995-11-01 | 2003-05-08 | University Of Southern California | Expression of cyclin G1 in tumors |
| DE69839243T2 (de) * | 1997-04-10 | 2009-04-30 | University Of Southern California, Los Angeles | Sich an extrazelluläre matrixbestandteile anbindende modifizierte proteine |
| US6746676B1 (en) * | 1998-04-20 | 2004-06-08 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Chlamydia proteins and their uses |
| US20060292121A1 (en) * | 1998-04-29 | 2006-12-28 | Hall Frederick L | Retroviral vectors including modified envelope escort protein |
| US6876760B1 (en) * | 2000-12-04 | 2005-04-05 | Cytokinetics, Inc. | Classifying cells based on information contained in cell images |
| US7151847B2 (en) * | 2001-02-20 | 2006-12-19 | Cytokinetics, Inc. | Image analysis of the golgi complex |
| DE60040292D1 (de) * | 1999-07-20 | 2008-10-30 | Univ Southern California | Identifizierung pluripotenter prämesenchymaler, prähämotopoietischer vorläuferzellen |
| WO2002044394A2 (en) | 2000-11-29 | 2002-06-06 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| US7218764B2 (en) * | 2000-12-04 | 2007-05-15 | Cytokinetics, Inc. | Ploidy classification method |
| US7016787B2 (en) * | 2001-02-20 | 2006-03-21 | Cytokinetics, Inc. | Characterizing biological stimuli by response curves |
| US6956961B2 (en) * | 2001-02-20 | 2005-10-18 | Cytokinetics, Inc. | Extracting shape information contained in cell images |
| US20040071328A1 (en) * | 2001-09-07 | 2004-04-15 | Vaisberg Eugeni A. | Classifying cells based on information contained in cell images |
| AU2003235316A1 (en) * | 2002-08-23 | 2004-03-11 | Japan Science And Technology Agency | Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thereof |
| US20070178066A1 (en) * | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| EP1682574A2 (en) * | 2003-09-15 | 2006-07-26 | Cenix Bioscience GmbH | The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| US20050273271A1 (en) * | 2004-04-05 | 2005-12-08 | Aibing Rao | Method of characterizing cell shape |
| US20070031818A1 (en) * | 2004-07-15 | 2007-02-08 | Cytokinetics, Inc., A Delaware Corporation | Assay for distinguishing live and dead cells |
| US7323318B2 (en) * | 2004-07-15 | 2008-01-29 | Cytokinetics, Inc. | Assay for distinguishing live and dead cells |
| US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
| US20110130444A1 (en) * | 2007-05-04 | 2011-06-02 | Stefan Moisyadi | Methods and compositions for targeted delivery of gene therapeutic vectors |
| US9291425B2 (en) * | 2013-05-24 | 2016-03-22 | Patrol Incident Gear, Llc. | Weapon sling |
| CN113671197B (zh) * | 2021-08-19 | 2023-08-08 | 四川沃文特生物技术有限公司 | 一种缓冲液、校准品、试剂盒、制备方法及用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06296489A (ja) * | 1992-11-20 | 1994-10-25 | Univ Texas Syst | 網膜芽腫−関連タンパク質をコードする細胞性遺伝子 |
-
1994
- 1994-10-24 CZ CZ961119A patent/CZ111996A3/cs unknown
- 1994-10-24 SK SK489-96A patent/SK48996A3/sk unknown
- 1994-10-24 US US08/328,254 patent/US5710022A/en not_active Expired - Fee Related
- 1994-10-24 WO PCT/US1994/012162 patent/WO1995011309A2/en not_active Ceased
- 1994-10-24 AU AU80885/94A patent/AU8088594A/en not_active Abandoned
- 1994-10-24 JP JP7512251A patent/JPH09507744A/ja active Pending
- 1994-10-24 EP EP94932002A patent/EP0723595A1/en not_active Ceased
- 1994-10-24 BR BR9407874A patent/BR9407874A/pt not_active Application Discontinuation
- 1994-10-24 CN CN94193875A patent/CN1133616A/zh active Pending
- 1994-10-24 CA CA002173978A patent/CA2173978A1/en not_active Abandoned
- 1994-10-24 HU HU9601023A patent/HUT74839A/hu unknown
- 1994-10-24 PL PL94314179A patent/PL314179A1/xx unknown
-
1996
- 1996-04-16 FI FI961665A patent/FI961665A7/fi not_active Application Discontinuation
- 1996-04-19 NO NO961571A patent/NO961571L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9601023D0 (en) | 1996-06-28 |
| NO961571D0 (no) | 1996-04-19 |
| EP0723595A1 (en) | 1996-07-31 |
| BR9407874A (pt) | 1996-10-29 |
| WO1995011309A2 (en) | 1995-04-27 |
| WO1995011309A3 (en) | 1995-06-08 |
| CA2173978A1 (en) | 1995-04-27 |
| HUT74839A (en) | 1997-02-28 |
| SK48996A3 (en) | 1996-10-02 |
| CZ111996A3 (en) | 1996-10-16 |
| US5710022A (en) | 1998-01-20 |
| PL314179A1 (en) | 1996-08-19 |
| FI961665A7 (fi) | 1996-06-06 |
| FI961665A0 (fi) | 1996-04-16 |
| JPH09507744A (ja) | 1997-08-12 |
| AU8088594A (en) | 1995-05-08 |
| CN1133616A (zh) | 1996-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO961571L (no) | Nytt, mitotisk kjernefosfoprotein: mitosin | |
| Pedersen et al. | Cholesterol side-chain cleavage in the rat adrenal cortex: isolation of a cycloheximide-sensitive activator peptide. | |
| Moorhead et al. | Purification of type 1 protein (serine/threonine) phosphatases by microcystin‐Sepharose affinity chromatography | |
| Westall et al. | Essential chemical requirements for induction of allergic encephalomyelitis | |
| Thim et al. | Isolation and characterization of putative trefoil peptide receptors | |
| Südhof et al. | Cassette of eight exons shared by genes for LDL receptor and EGF precursor | |
| Jbara et al. | Chemical synthesis of phosphorylated histone H2A at Tyr57 reveals insight into the inhibition mode of the SAGA deubiquitinating module | |
| Palmisano et al. | The phosphorylation pattern of bovine heart complex I subunits | |
| Quadroni et al. | Phosphorylation of calmodulin alters its potency as an activator of target enzymes | |
| Cleverley et al. | Identification of novel in vitro PKA phosphorylation sites on the low and middle molecular mass neurofilament subunits by mass spectrometry | |
| DeLange et al. | A histone-like protein (HTa) from Thermoplasma acidophilum. I. Purification and properties. | |
| US6228989B1 (en) | Peptide substrates phosphorylated by P21-activated protein kinase | |
| Lin et al. | Comprehensive characterization of swine cardiac troponin T proteoforms by top-down mass spectrometry | |
| Bergquist et al. | Identification of nuclei associated proteins by 2D-gel electrophoresis and mass spectrometry | |
| Juris et al. | Identification of otubain 1 as a novel substrate for the Yersinia protein kinase using chemical genetics and mass spectrometry | |
| Welker et al. | Two new structured intermediates in the oxidative folding of RNase A | |
| Otin et al. | The complete amino acid sequence of human complex-forming glycoprotein heterogeneous in charge (protein HC) from one individual | |
| Gäde et al. | Unique translational modification of an invertebrate neuropeptide: a phosphorylated member of the adipokinetic hormone peptide family | |
| Bradford et al. | Primary structure around the lipoate-attachment site on the E2 component of bovine heart pyruvate dehydrogenase complex | |
| Sekimizu et al. | Evidence that stimulatory factor (s) of RNA polymerase II participates in accurate transcription in a HeLa cell lysate. | |
| Rao et al. | Identification by mass spectrometry of a new α-tubulin isotype expressed in human breast and lung carcinoma cell lines | |
| Robertson et al. | Complete Assignment of Disulfide Bonds in Bovine Dopamine. beta.-Hydroxylase | |
| Schneider et al. | Phosphorylation of the major Drosophila lamin in vivo: site identification during both M-phase (meiosis) and interphase by electrospray ionization tandem mass spectrometry | |
| Horikoshi et al. | Structural relationships of the three stimulatory factors of RNA polymerase II from Ehrlich ascites tumor cells. | |
| Graham et al. | Evidence for the biosynthesis of a prolactin‐releasing factor from the ovine pars tuberalis, which is distinct from thyrotropin‐releasing hormone |